Skip to main content
. Author manuscript; available in PMC: 2025 Jan 1.
Published in final edited form as: Blood Rev. 2023 Oct 18;63:101139. doi: 10.1016/j.blre.2023.101139

Table 3.

Factors influencing the likelihood of romiplostim response in CIT.

Response Less Likely Response More Likely
Bone marrow infiltration by tumor Solid tumor with no bone metastasis
Dramatic elevations of endogenous thrombopoietin (>10–20 times upper limit of normal) Normal or modest elevation (<5 times upper limit of normal) of endogenous thrombopoietin
Prior temozolomide treatment
Prior pelvic irradiation
Diffuse bone metastases
Lymphoid malignancy involving bone marrow